MDxHealth SA
Index- P/E- EPS (ttm)-2.81 Insider Own- Shs Outstand15.60M Perf Week1.39%
Market Cap124.93M Forward P/E- EPS next Y-2.21 Insider Trans- Shs Float3.99M Perf Month-1.23%
Income- PEG- EPS next Q-0.47 Inst Own20.55% Short Float0.09% Perf Quarter0.13%
Sales22.24M P/S5.62 EPS this Y- Inst Trans- Short Ratio0.06 Perf Half Y-15.86%
Book/sh1.81 P/B4.43 EPS next Y1.80% ROA- Target Price15.33 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range6.20 - 13.17 Perf YTD-15.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.46% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low24.35% ATR0.61
Employees- Current Ratio- Sales Q/Q34.10% Oper. Margin- RSI (14)49.93 Volatility7.34% 6.25%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.01 Prev Close8.01
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume57.39K Price7.71
Recom1.30 SMA202.04% SMA50-0.28% SMA200-10.18% Volume134 Change-3.75%
May-25-22 04:00PM  
May-19-22 04:00PM  
Apr-27-22 04:00PM  
Apr-25-22 04:00PM  
Mar-30-22 04:30PM  
Mar-02-22 04:00PM  
Feb-17-22 04:00PM  
Feb-09-22 04:00PM  
Dec-10-21 06:01PM  
Nov-22-21 05:00PM  
Nov-15-21 05:00PM  
Nov-09-21 03:38PM  
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.